

Statement of Audited Standalone Financial Results for the Quarter and Year Ended on 31/03/2019

(Rs. In Lacs other than EPS)

Sr. No.	Particulars	Quarter Ended			Year Ended	
		31/03/2019	31/12/2018	31/03/2018	31/03/2019	31/03/2018
		Audited	Unaudited	Audited	Audited	Audited
1	Revenue from Operations	3512.59	3227.58	3005.82	12264.43	11467.42
2	Other Income	93.24	66.72	64.81	340.97	339.40
3	Total income	3605.83	3294.30	3070.63	12605.40	11806.82
4	Expenses					
	(a) Cost of Materials Consumed	233.92	475.90	336.95	1184.31	986.21
	(b) Purchase of Stock-in-trade	780.01	653.93	757.88	2690.71	2064.62
	(c) Changes in inventories of Finished Goods, Stock-in-trade and WIP	-59.71	-159.40	53.38	-249.39	348.29
	(d) Employee benefit expenses	821.83	794.58	740.06	3120.49	2769.18
	(e) Finance Costs	9.62	10.70	12.64	38.59	41.21
	(f) Depreciation and Amortisation Expense	35.16	35.31	38.21	135.30	150.02
	(g) Other expenses	845.78	825.78	266.96	3022.05	2920.40
	Total Expenses	2666.61	2636.80	2206.08	9942.06	9279.93
5	Profit before exceptional items & Tax	939.22	657.50	864.55	2663.34	2526.89
6	Exceptional Items	0.00	0.00	0.00	0.00	0.00
7	Profit before tax	939.22	657.50	864.55	2663.34	2526.89
8	Tax Expense					
	(i) Current Tax	252.00	200.00	315.00	752.00	830.00
	(ii) Income Tax for previous years	0.00	-4.72	14.24	-37.52	14.24
	(ii) Deferred Tax	-2.23	15.98	-22.47	-30.92	-38.57
9	Profit after tax for the period	689.45	446.24	557.78	1979.78	1721.22
10	Other Comprehensive Income					
	(i) Items that will not be reclassified to profit or loss	-53.76	8.93	-97.97	-44.97	-70.38
	(ii) Income Tax relating to Items that will not be reclassified to profit or loss	17.68	0.00	0.00	17.68	0.00
	(iii) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
	(iv) Income Tax relating to Items that will be reclassified to profit or loss	12.20	-1.52	-0.03	0.00	-0.04
11	Total Comprehensive Income for the period	665.57	453.65	459.78	1952.49	1650.80
12	Paid up Equity Share Capital (F.V. Rs.10/- each)	458.94	458.94	458.94	458.94	458.94
13	Earnings Per Share (in Rs.) (F.V. Rs.10/-) Basic and Diluted	15.02	9.72	12.15	43.14	37.50

Notes:

1 The Company has adopted Indian Accounting Standards (IND AS) prescribed under section 133 of the

Science hai toh Hope hai Hope hai toh Health hai Health hai toh Happiness hai 1/4

Companies Act 2013, read with relevant rules issued there under from 1st April, 2017 and accordingly, these standalone audited financial results (including figures for the previous quarters and year ended 31st March, 2018) have been prepared in accordance with the recognition and measurement principles laid down in Ind AS.

- 2 The Board of Directors has recommended dividend of Rs. 10.20 (102%) per equity share of Rs.10/- each of the company for the financial year 2018-19.
- 3 The above statement of audited standalone financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meeting held on 28th May, 2019.
- 4 The figures for the quarter ended 31st March 2019 are the balancing figures between audited figures for the year ended on 31st March 2019 and published year to date figures upto to the third quarter ended on 31st December 2018.
- 5 The Company is dealing exclusively in Pharmaceuticals business segment, hence segment wise reporting is not applicable.
- 6 The figures of the previous year/period have been regrouped/recast/rearranged to render them comparable with figures of the current period.
- 7 (a) An amount of Rs. 25,04,490/- being GST input credit for the previous period transferred to expenses account during the last quarter of the financial year 2018-19.
(b) As per actuarial report an amount of Rs. 45,08,411/- remitted to L I C towards Gratuity for the previous period transferred to Other Comprehensive Income during the last quarter of the financial year 2018-19.
- 8 Statement of Assets and Liabilities as at 31.03.2019 is as per Annexure - A, attached.
- 9 Cashflow statement as at 31.03.2019 is as per Annexure - B, attached.

Place : Mumbai
Date : 28th May, 2019

By order of the Board
For Jenburkt Pharmaceuticals Ltd.


(ASHISH U BHUTA)

CHAIRMAN AND MANAGING DIRECTOR



Annexure - A				
Standalone Statement of Assets and Liabilities				
			(Rs.in Lacs)	
Sr. No.	Particulars		AS AT 31/03/2019	AS AT 31/03/2018
			(Unaudited)	(Audited)
(A)		ASSETS		
(1)		Non Current Assets		
	(a)	Property, Plants & Equipments	943.16	944.91
	(b)	Goodwill	0.14	0.14
	(c)	Other Intangible assets	15.89	11.78
	(d)	Capital work in Progress	99.00	0.00
	(e)	Financial Assets		
	(i)	Investments	185.61	162.82
	(ii)	Loans	16.78	10.30
	(f)	Deferred Tax Assets (Net)	36.81	0.00
	(f)	Other Non Current Assets	18.31	25.03
(2)		Current Assets		
	(a)	Inventories	983.12	680.44
	(b)	Financial Assets		
	(i)	Investments	352.10	378.78
	(ii)	Trade receivables	2289.49	1253.78
	(iii)	Cash and cash equivalents	122.68	118.37
	(iv)	Bank balance other than (iii)	5047.33	3992.98
	(v)	Loans	31.64	28.84
	(vi)	Others	59.80	53.41
	(c)	Other current assets	80.63	85.56
		Total Assets	10282.49	7747.14
(B)		EQUITY AND LIABILITIES		
		Equity		
	(a)	Equity Share capital	458.94	458.94
	(b)	Other Equity - Reserves & Surplus	7287.61	5667.09
		Liabilities		
(1)		Non Current Liabilities		
	(a)	Financial Liabilities - Borrowings	0.00	23.59
	(b)	Deferred tax liabilities (Net)	0.00	11.79
	(c)	Other non-current liabilities	274.38	278.79
(2)		Current Liabilities		
	(a)	Financial Liabilities		
	(i)	Borrowings	746.94	0.53
	(ii)	Trade payables	654.89	412.21
	(iii)	Other financial liabilities	626.92	677.77
	(b)	Other current liabilities	177.86	189.18
	(c)	Provisions	41.52	18.62
	(d)	Current tax liabilities (Net)	13.43	8.62
		Total Equity and Liabilities	10282.49	7747.14


By order of the Board
For Jenburkt Pharmaceuticals Ltd.


(ASHISH U BHUTA),

CHAIRMAN AND MANAGING DIRECTOR

Place : Mumbai

Date : 28th May, 2019

Annexure - B				
Cash Flow Statement as at 31/03/2019				
			31/03/2019	(Rs. in Lacs)
			31/03/2019	31/03/2018
A.		CASH FLOW FROM OPERATING ACTIVITIES :		
	a	Net Profit before tax	2663.34	2526.89
		Adjustments for :		
	i	Depreciation and Amortisation Expense	135.31	150.02
	ii	Profit on sale/written off of property, plant and equipment and intangible assets, net	3.48	-0.56
	iii	Finance Cost	38.59	41.21
	iv	Interest Income	-320.50	-289.50
	v	Dividend income	-23.37	-4.39
	vi	Gain on sale of Investment (Short/Long Term Capital Gain)	0.00	-4.43
	vii	Provision/write off for doubtful trade receivables/advances	0.34	-27.80
	viii	Net unrealised foreign exchange gain	1.28	-31.86
		Operating profit (Loss) before working capital changes	2498.47	2359.58
	b	MOVEMENTS IN WORKING CAPITAL		
	i	Increase or (Decrease) in Inventories	-302.68	394.13
	ii	Increase or (Decrease) in Trade Receivables	-1036.05	-291.83
	iii	Increase or (Decrease) in Other (Current & Non Current) Assets	5.26	-47.35
	iv	Increase or (Decrease) in Trade Payables	242.69	-189.41
	v	Increase or (Decrease) in Bank Borrowings	723.34	0.00
	vi	Increase or (Decrease) in Other (Current & Non Current) Liabilities	-67.87	313.35
	vii	Increase or (Decrease) in Provisions	-54.80	-81.56
	c	Cash used in operation	2008.37	2456.89
	i	Income Taxes paid	-709.68	-871.26
		Net cash used in operating activities (A)	1298.68	1585.63
B.		CASH FLOW FROM INVESTING ACTIVITIES :		
	i	Payments for purchase of Property, Plant and Equipment (Including Capital Work in Progress, Intangible Assets and Intangible Assets in Development)	-240.14	-45.35
	ii	Proceeds from disposal of property, plant and equipment and intangible assets	0.00	1.69
	iii	Purchase of Investments	-5010.66	-1596.28
	iv	Proceeds from Sale / Redemption of Investments	5047.29	1276.00
	v	Other Bank balances not considered as cash and cash equivalents		
		Bank Fixed Deposit made during the year	-3750.25	-6983.32
		Bank Fixed Deposit matured during the year	2611.36	7100.65
	vi	Current & Non Current Financial Loans (Net employee loans given / recovered)	-9.27	6.42
	vii	Interest Received	275.68	335.58
	viii	Dividend Received	23.37	4.39
		Net cash generated by investing activities (B)	-1052.63	99.78
C.		CASH FLOW FROM FINANCING ACTIVITIES :		
	i	Borrowings - Others	-0.53	-613.36
	ii	Finance Cost	-38.59	-41.06
	iii	Dividend paid	-146.00	-661.45
	iv	Tax on Dividend paid	-56.61	-104.69
	v	Payment towards Buyback with premium	0.00	-345.15
		Net cash used in financing activities (C)	-241.74	-1765.71
		NET INCREASE/DECREASE IN CASH AND CASH EQUIVALENT (A+B+C)	4.31	-80.30
		Cash and cash equivalent at the beginning of the year (1st April, 2018)	118.37	198.66
		Cash and cash equivalent as at the end of the year (31st March, 2019)	122.68	118.37
			4.31	-80.30
The accompanying notes 1 to 52 are integral part of these Financial Statements				
			By order of the Board	
			For Jenburkt Pharmaceuticals Ltd.	
				
			(ASHISH U BHUTA)	
Place : Mumbai			CHAIRMAN AND MANAGING DIRECTOR	
Date : 28 th May, 2019				